Kaken Pharmaceutical Co. Ltd. has synthesized signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of asthma, allergic rhinitis, chronic obstructive pulmonary disease, atopic dermatitis, nasal polyps, bullous pemphigoid, prurigo and urticaria, among others.